Perspective
Towards a framework for personalized healthcare: lessons learned from the field of rare diseases
Published Online:29 Sep 2010https://doi.org/10.2217/pme.10.52
Abstract
A large percentage of medicines do not work for the patient populations they are intended to treat. Increased knowledge regarding genomics and the underlying biological mechanism of diseases should help us be able to stratify patients into groups of likely responders and nonresponders, and to identify those patients for whom a treatment might do more harm than good. This article sets out different policy perspectives for the healthcare systems, and draws in on 25 years of particular experience from the rare disease and orphan drug field, to illuminate the pathway forward in relation to key implementation aspects of personalized healthcare. In principle, we submit that targeting medicines to preidentified groups for whom we can predict a beneficial outcome is a good thing for everyone – first of all for the patients, but also for all the other stakeholders, including payers, treating physicians and industry – because it has the potential to create sustainable and functioning healthcare systems directed to better health and prevention of disease. Personalized healthcare over time could also lead to shorter drug-development times because of lower rates of failure in late-stage drug development. Using orphan medicines to treat well-diagnosed patients suffering from a life-threatening or seriously debilitating rare disease, is an attempt to work according to these principles. As there is much that needs to be done to turn the promise into reality, we need to identify the barriers and challenges to transform the potential opportunities into real-life benefits, and what needs to be done in order to overcome them. Learning from the field of rare diseases and orphan drugs may provide, perhaps unexpectedly, some of the answers to public policy questions related to future (personalized) healthcare, but of course not all aspects, are common between the two fields.
Keywords:
Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest
Bibliography
- 1 Spear B, Heath-Chiozzi M, Huff J: Clinical application of pharmacogenetics. Trends Mol. Med.7(5),201–204 (2001).
- 2 Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR et al.: Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS ONE.4(2),e4439(2009).
- 3 Hamburg MA, Collins FS: The path to personalized medicine. N. Engl. J. Med.363(4),301–304 (2010).▪▪ Great perspective on how the leaders of US FDA and NIH see the path to personalized medicine and the role of their institutions towards it.
- 4 Feero WG, Guttmacher AE, Collins FS: Genomic medicine, an updated primer. N. Engl. J. Med.362(21),2001–2011 (2010).▪ Interesting introduction to genomic medicine and data regarding where we are and what it means.
- 5 Boon W, Moors E: Exploring emerging technologies using methaphors – a study of orphan drugs and pharmacogenomics. Soc. Sci. Med.66,1915–1927 (2008).▪ Interestingly, it is the only paper we could identify regarding similarities between orphan drugs and pharmacogenomics.
- 6 Varmus H: Ten years on – the human genome and medicine. N. Engl. J. Med.362(21),2028–2029 (2010)
- 7 Davis JC, Furstenthal L, Desai AA et al.: The microeconomics of personalized medicine. Nat. Rev. Drug Discov.8(4),279–286 (2009).▪▪ Original paper discussing that the barriers in personalized medicine are shifting from ‘omics to economics, pleading for alignment of incentives.
- 8 Haffner ME: Adopting orphan drugs – two dozen years of treating rare diseases. N.Engl. J. Med.354,445–447 (2006).
- 9 Tambuyzer E: Targeted therapies: a sustainable business model? Pharma. Focus Asia10,26–29 (2009).
- 10 Eichler HG, Bloechl-Daum B, Abadie E, Barnett D, König F, Pearson S: Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers. Nat. Rev. Drug Discov.9,277–291 (2010).▪ Original and interesting analysis on what is to come from the collaboration between regulators and payers.
- 11 Quinn B: Personalised medicine: changing Business Models. Pharma. Focus Asia10,30–33 (2009).
- 12 The Pink Sheet. 71(008),19 (2009).
- 13 Kubitza L: The growth of personalized medicine will drive alliances between diagnostic and pharmaceutical industries. Drug Discov. World17–24 (2009).
- 14 Blair E: Predictive tests and personalized medicine. Drug Discov. World10(4),27–31 (2009).▪ Interesting paper about the value of predictive tests with case studies.
- 15 McDonald C, Hernandez M, Gofman Y, Suchecki S, Schreier W: The five most common misdiagnoses: a meta-analysis of autopsy and malpractice data. Int. J. Fam. Pract.7,2 (2009).▪ Based on autopsy data, an original paper showing the importance of a correct diagnosis, as many patients apparently were not treated for the disease they had.
- 16 Eichler HG, Abadie E, Raine JM, Salmonson T: Safe drugs and the cost of good intentions. N. Engl. J. Med.360(2),1378–1380 (2009).
- 17 Schofield I: Burring the boundaries between regulatory approval and HTAs. Scrip News 1b (2009).
- 18 Garber AM, Tunis SR: Does comparative-effectiveness research threaten personalized medicine? N. Engl. J. Med.360(19),1925–1927 (2009).
- 19 Samani NJ, Tomaszewski M, Schunkert H: Comment: the personal genome – the future of personalised medicine? Lancet375,12497–11498 (2010).▪ Interesting short perspective on the ethical issues and counseling in relating to personalized medicine.
- 20 Borden EC, Raghavan D: Comments: personalizing medicine for cancer, the next decade. Nat. Rev. Drug Discov.9,343–344 (2010).
- 21 Meikle PJ, Hopwood JJ, Clague AE, Carey WF: Prevalence of lysosomal storage disorders. Batten data mapped from worldwide estimates. JAMA281,249–254 (1999).
- 101 Science/Business Report and Survey on Health for All, Care for You, 22 April 2010 www.sciencebusiness.net/reports/healthforall/PM_survey_results.pdf▪ Recent and original report on a European survey regarding personalized healthcare and how various stakeholders look at it today.
- 102 WHO: The World Medicines Situation: the rational use of medicines, 2004 http://apps.who.int/medicinedocs/en/d/Js6160e/10.html
- 103 The Case for Personalized Medicine, May 2009 www.PersonalizedMedicineCoalition.org/▪ Report from one of the most active groups worldwide on what personalized medicine will bring.
- 104 European Medicines Agency www.ema.europa.eu/pdfs/human/pharmaco genetics/3764609endraft.pdf
- 105 Rare Diseases Europe www.eurordis.org/about-rare-diseases
- 106 The annual 2010 European Conference for Good Clinical Practice, about Aspects of Personalised Medicine for Society. Brussels, Belgium, 26–27 January 2010 www.efgcp.be/Conference_details.asp?id=235&L1=10&L2=2&TimeRef=2▪▪ Including the presentation on which this paper has been based.
- 107 Hughes-Wilson W: Rare diseases and orphan drugs as a precursor to personalized medicine: analogies between the two fields www.europabio.org/Healthcare/events/Personalised-medicines-event-19-march-2010.htm
- 108 The Seven European Daughters of Eve http://mctiernan.com/mtdna.htm
- 109 National Cancer Institute www.cancer.gov/trwg/TRWG-definition-and-TR-continuum
- 110 European Medicine Agency conference: 10 years of orphan drug regulation in Europe, 3–4 May 2010 (including presentation by Erik Tambuyzer) www.ema.europa.eu/
- 111 Role of -omics in personalised medicine. Brussels, Belgium, 29–30 April 2010 http://ec.europa.eu/research/health/pdf/summary-report-omics-for-personalised-medicine-workshop_en.pdf▪▪ Recent report regarding the role of ‘omics in personalized medicine, by experts from all over Europe.
- 112 EU Orphan Medicinal Products Regulation EC 141/2000 http://ec.europa.eu/enterprise/sectors/pharmaceuticals/files/eudralex/vol-1/reg_2000_141/reg_2000_141_en.pdf▪▪ From where it all started in Europe for rare diseases as a health priority: the EUs regulation on orphan medicinal products. Europe is now the world’s most active geographical area on rare diseases as a health priority.
- 113 Orphanet report series www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_alphabetical_list.pdf
- 114 Orphan drugs: rising to the challenge to ensure a better future for 30 million patients in Europe, EURORDIS statement www.eurordis.org/sites/default/files/publications/Statement_Future_of_Orphan_Drugs_14_October_09.pdf▪ Interesting analysis by EURORDIS, the EU patient group for rare diseases, about myths in the field of rare diseases.
- 115 Rare Diseases Europe www.eurordis.org/sites/default/files/publications/Fact_Sheet_Eurordiscare2.pdf
- 116 Improving Access to Orphan Drugs for all affected EU citizens: EU-High Level Pharmaceutical Forum, 2 October 2008 http://ec.europa.eu/pharmaforum/pricing_en.htm.▪ Set of policy recommendations originally drafted by a multistakeholder working group within the High Level Pharmaceutical Forum and accepted by the Forum.
- 117 National Organization of Rare Diseases www.rarediseases.org/
- 118 Genetic Alliance www.geneticalliance.org/
- 119 Rare Diseases Europe www.eurordis.org
- 120 Patients Netword for Medical Research and Health www.egan.eu/
- 121 European Medicines Agency: About Us www.ema.europa.eu/htms/aboutus/emeaoverview.htm
- 122 The Innovative Medicines Iniative http://imi.europa.eu/index_en.html
- 123 Pharma 2020: Challenging Business Models, which path do you take? www.pwc.com/en_BE/be/pharma/pdf/Pharma-2020-Challenging-business-PwC-09 pdf
- 124 Diagnostics 2009: moving towards personalized medicine, PriceWaterhouseCoopers, 27 July 2009 www.pwc.com/us/en/healthcare/publications/diagnostics-2009-moving-towards-personalized-medicine.jhtml
- 125 Harrmonizing genetic testing across Europe www.eurogentest.org/▪ Website of the European genetic testing programme, quality improvement and cross-border collaboration.
- 126 American Association for Clinical Chemistry, Laboratory Medicine Practice Guidelines, Guidelines and Recommendations for Laboratory Analysis and Application of Pharmacogenetics to Clinical Practice, edited by Roland Valdes, Jr, Deborah Payne and Mark W Linder www.aacc.org/members/nacb/LMPG/OnlineGuide/PublishedGuidelines/LAACP/Pages/default.aspx
- 127 Biobanking and Biomolecular Resources Research Infrastructure (BBMRI) www.bbmri.eu/
- 128 Kim Edward S, Herbst Roy S, Lee JJ et al. The BATTLE trial (Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination): personalizing therapy for lung cancer. Presentation abstract AACR 2010, Washington, DC, USA, 21–27 April 2010 www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=b21e246a-e09a-4c90–9c59–874f7139d921&cKey=381a62d2–5602–443c-83cc-f9a828f19e1b&mKey=%7b0591FA3B-AFEF-49D2–8E65–55F41EE8117E%7d
- 129 STRATA group: report on the ethical, legal and social aspects of genetic testing http://ec.europa.eu/research/conferences/2004/genetic/pdf/report_en.pdf▪▪ Good example of what a multistakeholder committee can achieve even in very complex areas such as ethical, legal and social issues of genetic testing.
- 130 Gene therapy research on Parkinson disease www.bloomberg.com/apps/news?pid=20601202&sid=aNohgZxH.NlU#
- 131 Leber congenital Amaurosis gene therapy (also published in March 2010 in Science Translational Medicine) www.blindness.org/index.php?option=com_content&view=article&id=2062:new-study-paves-way-for-treating-second-eye-in-gene-therapy-clinical-trial&catid=65:retinitis-pigmentosa&Itemid=121
- 132 PTC Therapeutics www.ptcbio.com/2.4_faqs.aspx
